{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:28:19Z","timestamp":1793838499717,"version":"4.6.1"},"reference-count":104,"publisher":"Elsevier","isbn-type":[{"value":"9780323950572","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20365"],"award-info":[{"award-number":["20365"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.apha.2022.12.001","type":"book-chapter","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T08:22:56Z","timestamp":1683793376000},"page":"133-165","source":"Crossref","is-referenced-by-count":34,"title":["Cyclooxygenases and platelet functions"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.apha.2022.12.001_bb0010","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1194\/jlr.M041533","article-title":"Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation","volume":"54","author":"Aldrovandi","year":"2013","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0015","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/bs.apha.2022.12.001_bb0020","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/CIRCRESAHA.107.165936","article-title":"Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: Potential implications for cyclooxygenase-2 inhibition","volume":"102","author":"Arehart","year":"2008","journal-title":"Circulation Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/385081a0","article-title":"P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues","volume":"385","author":"Austrup","year":"1997","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2022.12.001_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838079","article-title":"Inflammation and cancer: From the development of personalized indicators to novel therapeutic strategies","volume":"13","author":"Ballerini","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0035","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1111\/bph.12677","article-title":"Pathophysiology of isoprostanes in the cardiovascular system: Implications of isoprostane-mediated thromboxane A2 receptor activation","volume":"171","author":"Bauer","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0040","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2017.07.004","article-title":"Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets","volume":"32","author":"Best","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.apha.2022.12.001_bb0045","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","article-title":"RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics","volume":"28","author":"Best","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.apha.2022.12.001_bb0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12079-020-00585-0","article-title":"A review of Prostanoid receptors: Expression, characterization, regulation, and mechanism of action","volume":"15","author":"Biringer","year":"2021","journal-title":"Journal of Cell Communication and Signaling"},{"key":"10.1016\/bs.apha.2022.12.001_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.blre.2009.04.001","article-title":"Platelet alpha-granules: Basic biology and clinical correlates","volume":"23","author":"Blair","year":"2009","journal-title":"Blood Reviews"},{"key":"10.1016\/bs.apha.2022.12.001_bb511","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1600-0854.2011.01225.x","article-title":"Exosome secretion: Molecular mechanisms and roles in immune responses","volume":"12","author":"Bobrie","year":"2011","journal-title":"Traffic"},{"key":"10.1016\/bs.apha.2022.12.001_bb0060","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1073\/pnas.061615598","article-title":"Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis","volume":"98","author":"Borsig","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2022.12.001_bb0065","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)60600-4","article-title":"Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial","volume":"377","author":"Bousser","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/bs.apha.2022.12.001_bb0070","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.3390\/ijms21239020","article-title":"Effect of Prostanoids on human platelet function: An overview","volume":"21","author":"Braune","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apha.2022.12.001_bb0075","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1146\/annurev.pharmtox.41.1.661","article-title":"Prostanoid receptors: Subtypes and signaling","volume":"41","author":"Breyer","year":"2001","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/JPR.S75160","article-title":"New insights into the use of currently available non-steroidal anti-inflammatory drugs","volume":"8","author":"Brune","year":"2015","journal-title":"Journal of Pain Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106506","article-title":"The specific deletion of cyclooxygenase-1 in megakaryocytes\/platelets reduces intestinal polyposis in ApcMin\/+ mice","volume":"185","author":"Bruno","year":"2022","journal-title":"Pharmacological Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0090","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/cancers10080253","article-title":"Antithrombotic agents and cancer","volume":"10","author":"Bruno","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.apha.2022.12.001_bb0095","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1007\/s00018-017-2536-7","article-title":"Platelets as crucial partners for tumor metastasis: From mechanistic aspects to pharmacological targeting","volume":"74","author":"Contursi","year":"2017","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/bs.apha.2022.12.001_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115252","article-title":"Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk","volume":"205","author":"Contursi","year":"2022","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105744","article-title":"Low-dose aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained","volume":"170","author":"D'Agostino","year":"2021","journal-title":"Pharmacological Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-642-29423-5_11","article-title":"Thromboxane receptors antagonists and\/or synthase inhibitors","volume":"210","author":"Dav\u00ec","year":"2012","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0115","doi-asserted-by":"crossref","first-page":"9585","DOI":"10.3390\/ijms21249585","article-title":"Multifaceted functions of platelets in cancer: From tumorigenesis to liquid biopsy tool and drug delivery system","volume":"21","author":"Dovizio","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apha.2022.12.001_bb0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10555-018-9730-4","article-title":"Platelets and extracellular vesicles in cancer: Diagnostic and therapeutic implications","volume":"37","author":"Dovizio","year":"2018","journal-title":"Cancer Metastasis Reviews"},{"key":"10.1016\/bs.apha.2022.12.001_bb516","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-642-30331-9_3","article-title":"Mode of action of aspirin as a chemopreventive agent","volume":"191","author":"Dovizio","year":"2013","journal-title":"Recent Results in Cancer Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2017.01.003","article-title":"Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process","volume":"89","author":"Dovizio","year":"2017","journal-title":"Vascular Pharmacology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0130","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1096\/fasebj.12.12.1063","article-title":"Cyclooxygenase in biology and disease","volume":"12","author":"Dubois","year":"1998","journal-title":"The FASEB Journal"},{"key":"10.1016\/bs.apha.2022.12.001_bb0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/01.RES.0000214553.37930.3e","article-title":"De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin","volume":"98","author":"Evangelista","year":"2006","journal-title":"Circulation Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0140","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1172\/JCI10881","article-title":"Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation","volume":"107","author":"Fabre","year":"2001","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2022.12.001_bb0145","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1111\/j.1538-7836.2010.04020.x","article-title":"Thromboxane antagonism with terutroban in peripheral arterial disease: The TAIPAD study","volume":"8","author":"Fiessinger","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/bs.apha.2022.12.001_bb0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12265-013-9529-1","article-title":"Antiplatelet therapy: Targeting the TxA2 pathway","volume":"7","author":"Fontana","year":"2014","journal-title":"Journal of Cardiovascular Translational Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0155","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.thromres.2015.05.027","article-title":"Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease","volume":"136","author":"Friedman","year":"2015","journal-title":"Thrombosis Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0160","doi-asserted-by":"crossref","first-page":"17901","DOI":"10.3390\/ijms151017901","article-title":"Platelets: Still a therapeutical target for haemostatic disorders","volume":"15","author":"Geraldo","year":"2014","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apha.2022.12.001_bb0165","article-title":"Novel approaches to antiplatelet therapy","volume":"13","author":"Gresele","year":"2022","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0170","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2022.12.001_bb0175","doi-asserted-by":"crossref","first-page":"32462","DOI":"10.18632\/oncotarget.8655","article-title":"Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells","volume":"7","author":"Guillem-Llobat","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.apha.2022.12.001_bb0180","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1021\/cr200246d","article-title":"Lipoxygenase and leukotriene pathways: Biochemistry, biology, and roles in disease","volume":"111","author":"Haeggstrom","year":"2011","journal-title":"Chemical Reviews"},{"key":"10.1016\/bs.apha.2022.12.001_bb0185","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4103\/2045-8932.114760","article-title":"On the origin of microparticles: From \u201cplatelet dust\u201d to mediators of intercellular communication","volume":"3","author":"Hargett","year":"2013","journal-title":"Pulm Circ"},{"key":"10.1016\/bs.apha.2022.12.001_bb0190","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.193.2.255","article-title":"Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2","volume":"193","author":"Hirai","year":"2001","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.apha.2022.12.001_bb0195","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1021\/cr200010h","article-title":"Prostanoid receptors","volume":"111","author":"Hirata","year":"2011","journal-title":"Chemical Reviews"},{"key":"10.1016\/bs.apha.2022.12.001_bb0200","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI118518","article-title":"Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to leu mutation","volume":"97","author":"Hirata","year":"1996","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2022.12.001_bb0205","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00121490","article-title":"Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin\/thromboxane A2 system","volume":"1","author":"Honn","year":"1983","journal-title":"Clinical & Experimental Metastasis"},{"key":"10.1016\/bs.apha.2022.12.001_bb0210","first-page":"991","article-title":"Novel antiplatelet therapies","author":"Kolandaivelu","year":"2019","journal-title":"Platelets (Fourth Edition)"},{"key":"10.1016\/bs.apha.2022.12.001_bb0215","first-page":"633","article-title":"Prostaglandin E synthase: A terminal enzyme for prostaglandin E2 biosynthesis","volume":"38","author":"Kudo","year":"2005","journal-title":"Journal of Biochemistry and Molecular Biology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0220","doi-asserted-by":"crossref","first-page":"12572","DOI":"10.1016\/S0021-9258(17)38909-3","article-title":"Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents","volume":"260","author":"Kulmacz","year":"1985","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2022.12.001_bb0225","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: Improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0230","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1073\/pnas.76.1.121","article-title":"Rapid inactivation of cyclooxygenase activity after stimulation of intact platelets","volume":"76","author":"Lapetina","year":"1979","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2022.12.001_bb0235","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1016\/S0021-9258(17)36820-5","article-title":"Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin","volume":"269","author":"Lecomte","year":"1994","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2022.12.001_bb0240","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0090-6980(87)90107-9","article-title":"Binding of a thromboxane A2\/prostaglandin H2 agonist [3H]U46619 to washed human platelets","volume":"33","author":"Liel","year":"1987","journal-title":"Prostaglandins"},{"key":"10.1016\/bs.apha.2022.12.001_bb0245","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1172\/JCI26885","article-title":"Platelet genomics and proteomics in human health and disease","volume":"115","author":"Macaulay","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2022.12.001_bb0250","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/ATVBAHA.118.310955","article-title":"Novel antiplatelet therapies for atherothrombotic diseases","volume":"39","author":"Majithia","year":"2019","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(99)00015-8","article-title":"Platelet dense granules: Structure, function and implications for haemostasis","volume":"95","author":"McNicol","year":"1999","journal-title":"Thrombosis Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1074\/mcp.M300063-MCP200","article-title":"Integration of proteomic and genomics in platelets: A profile of platelet proteins and platelet-specific genes","volume":"3","author":"McRedmond","year":"2004","journal-title":"Molecular & Cellular Proteomics"},{"key":"10.1016\/bs.apha.2022.12.001_bb0265","series-title":"Platelets","author":"Michelson","year":"2013"},{"key":"10.1016\/bs.apha.2022.12.001_bb0270","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/01.ATV.18.8.1248","article-title":"The F2-isoprostane 8-epiprostaglandin F2alpha increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO","volume":"18","author":"Minuz","year":"1998","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0275","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12890-020-1113-2","article-title":"NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension","volume":"20","author":"Mulvaney","year":"2020","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1016\/bs.apha.2022.12.001_bb0280","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: Structures, properties, and functions","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiological Reviews"},{"key":"10.1016\/bs.apha.2022.12.001_bb0285","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ehj.2004.07.013","article-title":"Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study","volume":"25","author":"Neri Serneri","year":"2004","journal-title":"European Heart Journal"},{"key":"10.1016\/bs.apha.2022.12.001_bb0290","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1172\/JCI26891","article-title":"The biogenesis of platelets from megakaryocyte proplatelets","volume":"115","author":"Patel","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2022.12.001_bb0295","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2022.12.001_bb0300","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bbalip.2014.09.016","article-title":"Cyclooxygenase inhibitors: From pharmacology to clinical read-outs","volume":"1851","author":"Patrignani","year":"2015","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/bs.apha.2022.12.001_bb0305","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2016.05.083","article-title":"Aspirin and cancer","volume":"68","author":"Patrignani","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0310","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/09537104.2018.1492105","article-title":"Aspirin, platelet inhibition and cancer prevention","volume":"29","author":"Patrignani","year":"2018","journal-title":"Platelets"},{"key":"10.1016\/bs.apha.2022.12.001_bb0315","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1476-5381.1996.tb15535.x","article-title":"Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F2-isoprostane formation","volume":"118","author":"Patrignani","year":"1996","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0320","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"key":"10.1016\/bs.apha.2022.12.001_bb0325","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI200113418","article-title":"Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs","volume":"108","author":"Patrono","year":"2001","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2022.12.001_bb512","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/367243a0","article-title":"The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1","volume":"367","author":"Picot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2022.12.001_bb0330","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.tips.2017.03.003","article-title":"Targeting the prostacyclin pathway: Beyond pulmonary arterial hypertension","volume":"38","author":"Pluchart","year":"2017","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/bs.apha.2022.12.001_bb0335","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.bbalip.2014.10.008","article-title":"Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid","volume":"1851","author":"Powell","year":"2015","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/bs.apha.2022.12.001_bb0340","doi-asserted-by":"crossref","first-page":"9800","DOI":"10.1074\/jbc.270.17.9800","article-title":"Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha","volume":"270","author":"Pratico","year":"1995","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2022.12.001_bb0345","first-page":"888","volume":"89","author":"Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2\/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT)","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/bs.apha.2022.12.001_bb0350","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0355","doi-asserted-by":"crossref","first-page":"954","DOI":"10.5603\/CJ.a2020.0164","article-title":"Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding?","volume":"28","author":"Rogula","year":"2021","journal-title":"Cardiology Journal"},{"key":"10.1016\/bs.apha.2022.12.001_bb0360","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1527-3466.2001.tb00058.x","article-title":"Ifetroban sodium: An effective TxA2\/PGH2 receptor antagonist","volume":"19","author":"Rosenfeld","year":"2006","journal-title":"Cardiovascular Drug Reviews"},{"key":"10.1016\/bs.apha.2022.12.001_bb513","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2022.12.001_bb0365","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/bs.apha.2022.12.001_bb517","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/cells11040725","article-title":"Antiplatelet agents affecting GPCR signaling implicated in tumor metastasis","volume":"11","author":"Rovati","year":"2022","journal-title":"Cells"},{"key":"10.1016\/bs.apha.2022.12.001_bb0370","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1182\/blood.2019003976","article-title":"Lessons to learn from tumor-educated platelets","volume":"137","author":"Roweth","year":"2021","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2022.12.001_bb0375","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1538-7836.2003.00260.x","article-title":"Von Willebrand factor, platelets and endothelial cell interactions","volume":"1","author":"Ruggeri","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/bs.apha.2022.12.001_bb0380","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1124\/jpet.119.259382","article-title":"Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice","volume":"370","author":"Sacco","year":"2019","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.apha.2022.12.001_bb0385","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pr.59.3.1","article-title":"Membrane prostaglandin E synthase-1: A novel therapeutic target","volume":"59","author":"Samuelsson","year":"2007","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/bs.apha.2022.12.001_bb514","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1021\/bi1003298","article-title":"Comparison of cyclooxygenase-1 crystal structures: Cross-talk between monomers comprising cyclooxygenase-1 homodimers","volume":"49","author":"Sidhu","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/bs.apha.2022.12.001_bb0390","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1476-5381.2009.00121.x","article-title":"Regulation of RhoGEF proteins by G12\/13-coupled receptors","volume":"158","author":"Siehler","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0395","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.56.3.3","article-title":"Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition","volume":"56","author":"Simmons","year":"2004","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/bs.apha.2022.12.001_bb0400","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2217\/clp.10.11","article-title":"Thromboxane and the thromboxane receptor in cardiovascular disease","volume":"5","author":"Smyth","year":"2010","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0405","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1194\/jlr.R800094-JLR200","article-title":"Prostanoids in health and disease","volume":"50","author":"Smyth","year":"2009","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0410","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI59262","article-title":"Niacin and biosynthesis of PGD\u2082 by platelet COX-1 in mice and humans","volume":"122","author":"Song","year":"2012","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2022.12.001_bb0415","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1194\/jlr.R800038-JLR200","article-title":"Arachidonic acid cytochrome P450 epoxygenase pathway","volume":"50","author":"Spector","year":"2009","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0420","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-642-29423-5_3","article-title":"Platelet signaling","volume":"210","author":"Stalker","year":"2012","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0425","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1074\/jbc.M110.124933","article-title":"Comprehensive biochemical analysis of rare prostacyclin receptor variants: Study of association of signaling with coronary artery obstruction","volume":"286","author":"Stitham","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2022.12.001_bb0430","doi-asserted-by":"crossref","first-page":"15439","DOI":"10.1074\/jbc.M201187200","article-title":"Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism","volume":"277","author":"Stitham","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2022.12.001_bb0435","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/14740338.2017.1338272","article-title":"Nonsteroidal anti-inflammatory drugs and cardiovascular safety\u2014translating pharmacological data into clinical readouts","volume":"16","author":"Tacconelli","year":"2017","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/bs.apha.2022.12.001_bb0440","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1074\/jbc.275.12.8501","article-title":"Different catalytically competent arrangements of arachidonic acid within the cyclooxygenase active site of prostaglandin endoperoxide H synthase-1 lead to the formation of different oxygenated products","volume":"275","author":"Thuresson","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2022.12.001_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.718002","article-title":"Biochemical and structural characteristics, gene regulation, physiological, pathological and clinical features of lipocalin-type prostaglandin D2 synthase as a multifunctional lipocalin","volume":"12","author":"Urade","year":"2021","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/bs.apha.2022.12.001_bb0450","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.2022.4983","article-title":"Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement","volume":"327","author":"US Preventive Services Task Force","year":"2022","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/bs.apha.2022.12.001_bb0455","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1172\/JCI97953","article-title":"Role of prostanoids in gastrointestinal cancer","volume":"128","author":"Wang","year":"2018","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2022.12.001_bb0460","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1158\/1535-7163.MCT-19-1106","article-title":"Repurposing of a thromboxane receptor inhibitor based on a novel role in metastasis identified by phenome-wide association study","volume":"19","author":"Werfel","year":"2020","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.apha.2022.12.001_bb0465","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011902","article-title":"Antagonism of the thromboxane-prostanoid receptor as a potential therapy for cardiomyopathy of muscular dystrophy","volume":"8","author":"West","year":"2019","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/bs.apha.2022.12.001_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107393","article-title":"Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic","volume":"203","author":"Xiang","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/bs.apha.2022.12.001_bb0475","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2008-03-145821","article-title":"Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression","volume":"114","author":"Yang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2022.12.001_bb0480","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1073\/pnas.0811834106","article-title":"Prostaglandin F2 elevates blood pressure and promotes atherosclerosis","volume":"106","author":"Yu","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2022.12.001_bb0485","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1074\/jbc.M808634200","article-title":"Cyclooxygenase allosterism, fatty acid-mediated cross-talk between monomers of cyclooxygenase homodimers","volume":"284","author":"Yuan","year":"2009","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2022.12.001_bb0490","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1179\/1743132812Y.0000000022","article-title":"Ozagrel for acute ischemic stroke: A meta-analysis of data from randomized controlled trials","volume":"34","author":"Zhang","year":"2012","journal-title":"Neurological Research"},{"key":"10.1016\/bs.apha.2022.12.001_bb0495","doi-asserted-by":"crossref","first-page":"s17","DOI":"10.1161\/ATVBAHA.107.160218","article-title":"Signal-dependent protein synthesis by activated platelets: New pathways to altered phenotype and function","volume":"28","author":"Zimmerman","year":"2008","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"}],"container-title":["Advances in Pharmacology","Bioactive Lipid Mediators in Cardiopulmonary Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358922000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358922000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:26:25Z","timestamp":1762359985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358922000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780323950572"],"references-count":104,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2022.12.001","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}